AlphAIalphai — Financial news for AI agents
news.alphastreet.comJUL 282 min read$TLRY

Tilray Brands Releases Q4 2026 Financial Results

Tilray Brands reported Q4 2026 adjusted EPS of $0.05, below the $0.21 consensus, and adjusted net income of $5.3M. Revenue rose to $281.7M, above the $246.3M consensus and up 25% from Q4 2025. Beverage revenue was $105.6M (+61% YoY).

Original reporting
news.alphastreet.com
Published Jul 28, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Tilray Brands Releases Q4 2026 Financial Results — source image
Source · news.alphastreet.com
Decision brief

The 30-second read

$TLRYNeutralMed
01

Why it matters

Traders may reprice the stock based on the earnings quality signal: strong top-line growth but weaker adjusted earnings, with analyst positioning described as mostly holds.

02

Market read

A revenue beat alongside an EPS miss is a classic mixed earnings setup, affecting expectations for margins and investment-phase execution.

03

What to watch

Without segment-level profitability, guidance, or cash flow, the EPS miss could reflect one-time items or investment spend that may not persist.

Relevance 7/10Novelty 6/10Timing: after-hours earnings release for Q4 2026

Background

The article summarizes Tilray’s Q4 2026 results, highlighting adjusted EPS and revenue versus consensus, plus growth by beverage and international medical cannabis.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

Tilray reported Q4 2026 adjusted EPS of $0.05, missing $0.21 consensus, while revenue rose to $281.7M, 14.4% above expectations.

Expected impact

Choppy trading risk around the earnings reaction, with focus shifting to profitability trajectory versus top-line momentum.

Evidence & confidence

The article provides both the EPS miss and revenue beat, but no guidance, cash flow, or margin detail to confirm whether the miss is transitory.

Market effects

Sector

Cannabis consumer and medical cannabis names may see read-across on whether revenue growth is translating into earnings power.

Regional

No specific regional catalyst beyond company results.

Global

Limited, as the article contains no cross-border regulatory or macro shock.

Counterpoint

What could challenge this read

The revenue outperformance (14.4% above consensus, +25% YoY) could outweigh the EPS miss if investors expect operating leverage to improve in subsequent quarters.

Key entities

  • company
    Tilray Brands, Inc.

    Reported Q4 2026 adjusted EPS of $0.05 (miss) and revenue of $281.7M (beat), with beverage and international medical cannabis growth.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 7
$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

simplywall.st7 min
JUL 30
$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

yahoo.com6 min
JUL 29
$TLRYMed

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

foodbusinessmea.com4 min
JUL 29
$TLRYMedAI 8/10

Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23%

Tilray Brands reported Q4 net revenue of $281.7 million for the period ended May 31, up 10.7% versus the $254.53 million consensus estimate, and shares rose 2.23% to $4.12 after hours. Adjusted EPS was $0.05, missing the $0.21 consensus. For FY26, net revenue rose 11% to $915.5 million; adjusted EBITDA increased to $61.1 million.

scanx.trade4 min